Agios Pharmaceuticals (Nasdaq: AGIO) has signed exclusive worldwide license agreement with fellow USA-based Alnylam Pharmaceuticals (Nasdaq: ALNY) to acquire the rights to develop and commercialize Alnylam’s novel pre-clinical siRNA targeting TMPRSS6, as a potential disease-modifying treatment for patients with polycythemia vera (PV).
This agreement combines Agios’ deep scientific expertise and capabilities in rare hematologic diseases with Alnylam’s industry-leading siRNA platform and strong track record of success.
It also follows the potential $2.8 billion deal that Alnylam announced last month with Swiss pharma giant Roche (ROG: SIX) to co-commercialize zilebesiran.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze